A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

PHASE1CompletedINTERVENTIONAL

Enrollment

190

Participants

Timeline

Start Date

May 14, 2019

Primary Completion Date

November 13, 2019

Study Completion Date

November 13, 2019

Conditions

Healthy Volunteers

Interventions

DRUG

SHP643

Participants will receive injection of SHP643.

Trial Locations (1)

Clinical Pharmacology of Miami, LLC, Miami